{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:20:58Z","timestamp":1788618058900,"version":"build-2803163510"},"reference-count":15,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background:<\/jats:title>\n<jats:p>Patients with reactive arthritis frequently present to dermatologists. However, there is paucity of information regarding its clinical aspects and management in dermatological literature.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Objective:<\/jats:title>\n<jats:p>To review the clinical features and management of patients with chronic reactive arthritis admitted to the dermatology department of a teaching hospital.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Methods:<\/jats:title>\n<jats:p>This was a retrospective analysis of patients with reactive arthritis admitted to the Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India from January 2016 to February 2018.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>Results:<\/jats:title>\n<jats:p>There were 12 males (disease duration 9\u2013180 months). Biologics were used in 9 (75%) patients on 16 different occasions, the most frequent being infliximab (<jats:italic>n<\/jats:italic> = 10 times), followed by adalimumab (<jats:italic>n<\/jats:italic> = 3), etanercept, secukinumab and itolizumab (<jats:italic>n<\/jats:italic> = 1 each), in combination with other systemic agents. Response rate with treatment regimens including biologics (69% responders, 31% partial responders) was statistically significantly better than those without biologics (27% responders, 46% partial responders, 27% nonresponders; <jats:italic>P<\/jats:italic> = 0.036), using a composite measure assessing improvement in skin and joint symptoms. Biologics were discontinued on 50% of the occasions, after a median of 3.5 months (range 1.5\u20137.5 months) because of satisfactory response (<jats:italic>n<\/jats:italic> = 4), therapeutic fatigue (<jats:italic>n<\/jats:italic> = 3) or adverse event (<jats:italic>n<\/jats:italic> = 1). After biologic discontinuation, the response was sustained for a median of 5 months (range 3\u20136 months) before disease exacerbation. The number of treatment switches increased with the follow-up duration (median three switches per patient, range 1\u20138). The median follow-up duration was 10.5 months (range 4\u201376 months).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st5\">\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Biologics produce rapid improvement in skin and joint symptoms in chronic reactive arthritis, but the response is not long-lasting. Patients with chronic reactive arthritis have a waxing and waning course despite regular treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st6\">\n<jats:title>Limitations:<\/jats:title>\n<jats:p>The limitations are retrospective design, small sample size and lack of a validated outcome measure.<\/jats:p>\n<\/jats:sec>","DOI":"10.4103\/ijdvl.ijdvl_519_18","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T08:56:02Z","timestamp":1562835362000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A retrospective case series of 12 patients with chronic reactive arthritis with emphasis on treatment outcome with biologics"],"prefix":"10.25259","volume":"87","author":[{"given":"Vishal","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Mohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/ard.38.Suppl_1.73","article-title":"Incomplete Reiter's syndrome: Clinical comparisons with classical triad","volume":"38","author":"Arnett","year":"1979","journal-title":"Ann Rheum Dis"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/art.1780240612","article-title":"Reiter's syndrome, Evaluation of preliminary criteria for definite disease","volume":"24","author":"Willkens","year":"1981","journal-title":"Arthritis Rheum"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00541187","article-title":"Reiter's disease in Northern India. A clinical and immunogenetic study","volume":"3","author":"Prakash","year":"1983","journal-title":"Rheumatol Int"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/ard.55.8.564","article-title":"Third International Workshop on Reactive Arthritis 23-26, September 1995, Berlin, Germany, Report and abstracts","volume":"55","author":"Kingsley","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/1529-0131(200004)43:4<720::AID-ANR2>3.0.CO;2-8","article-title":"Report on the Fourth International Workshop on Reactive Arthritis","volume":"43","author":"Sieper","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2310\/7750.2012.12048","article-title":"Reactive arthritis in India: A dermatologists' perspective","volume":"17","author":"Kanwar","year":"2013","journal-title":"J Cutan Med Surg"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-7","first-page":"358","article-title":"Pluse therapy with dexamethasone in Reiter's disease","volume":"48","author":"Pasricha","year":"1982","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-8","first-page":"323","article-title":"Pulse therapy as a cure for autoimmune diseases","volume":"69","author":"Pasricha","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rdc.2009.03.010","article-title":"Reactive arthritis: Clinical aspects and medical management","volume":"35","author":"Carter","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3899\/jrheum.121192","article-title":"Antibiotics for treatment of reactive arthritis: A systematic review and metaanalysis","volume":"40","author":"Barber","year":"2013","journal-title":"J Rheumatol"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21323","article-title":"Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: An open-label trial","volume":"53","author":"Flagg","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-12","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/art.30272","article-title":"Safety and efficacy of anti-tumor necrosis factor? therapy in ten patients with recent-onset refractory reactive arthritis","volume":"63","author":"Meyer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0889-857X(05)70037-5","article-title":"Reiter's syndrome, Diagnosis and clinical features","volume":"24","author":"Amor","year":"1998","journal-title":"Rheum Dis Clin North Am"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/0002-9343(79)90739-3","article-title":"A follow-up study of 48 patients with Reiter's syndrome","volume":"67","author":"Butler","year":"1979","journal-title":"Am J Med"},{"key":"10.4103\/ijdvl.IJDVL_519_18\/ref-15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/rheumatology\/39.2.148","article-title":"Development of a disease activity index for the assessment of reactive arthritis (DAREA)","volume":"39","author":"Eberl","year":"2000","journal-title":"Rheumatology (Oxford)"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/a-retrospective-case-series-of-12-patients-with-chronic-reactive-arthritis-with-emphasis-on-treatment-outcome-with-biologics\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/a-retrospective-case-series-of-12-patients-with-chronic-reactive-arthritis-with-emphasis-on-treatment-outcome-with-biologics\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T12:55:21Z","timestamp":1616504121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/a-retrospective-case-series-of-12-patients-with-chronic-reactive-arthritis-with-emphasis-on-treatment-outcome-with-biologics\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":15,"alternative-id":["10.4103\/ijdvl.IJDVL_519_18"],"URL":"https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_519_18","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"article-number":"227"}}